Literature DB >> 3008551

Rises in titers of antibody to human coronaviruses OC43 and 229E in Seattle families during 1975-1979.

O W Schmidt, I D Allan, M K Cooney, H M Foy, J P Fox.   

Abstract

Sequential serum specimens were obtained every four months during 1975-1979 from 44 children and adults of 10 Seattle families. The 419 specimens were tested for antibody to human coronaviruses OC43 and 229E by enzyme-linked immunosorbent assay (ELISA). Antibody titers were found to increase with age, and titers as well as frequency of rises were greater for OC43 than for 229E virus in all age groups. Significant antibody rises were most frequent in specimens bracketing the winter interval, but some also occurred in the spring-summer and summer-fall intervals. Concurrent significant antibody rises to OC43 virus in different members of the same family were observed in 15 instances, to 229E virus in seven instances, and to OC43 virus in some members and 229E virus in others in eight instances. Significant antibody rises to OC43 or 229E virus indicating reinfections were frequently observed throughout the three-year period but were always separated by at least two four-month intervals. Concurrent significant antibody rises to both 229E and OC43 viruses were seen only in three persons. Finally, the frequency of significant antibody rises in children, about one per person-year, was almost three times higher than in adults.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3008551      PMCID: PMC7110132          DOI: 10.1093/oxfordjournals.aje.a114315

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  22 in total

1.  Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum.

Authors:  Geoffrey J Gorse; Gira B Patel; Joseph N Vitale; Theresa Z O'Connor
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

2.  Possible Cross-Reactivity of Feline and White-Tailed Deer Antibodies against the SARS-CoV-2 Receptor Binding Domain.

Authors:  Trevor J Hancock; Peyton Hickman; Niloo Kazerooni; Melissa Kennedy; Stephen A Kania; Michelle Dennis; Nicole Szafranski; Richard Gerhold; Chunlei Su; Tom Masi; Stephen Smith; Tim E Sparer
Journal:  J Virol       Date:  2022-03-30       Impact factor: 6.549

3.  Development and application of an enzyme immunoassay for coronavirus OC43 antibody in acute respiratory illness.

Authors:  E P Gill; E A Dominguez; S B Greenberg; R L Atmar; B G Hogue; B D Baxter; R B Couch
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

4.  Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population.

Authors:  Emily G Severance; Ioannis Bossis; Faith B Dickerson; Cassie R Stallings; Andrea E Origoni; Anne Sullens; Robert H Yolken; Raphael P Viscidi
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

Review 5.  Lessons for COVID-19 Immunity from Other Coronavirus Infections.

Authors:  Alan Sariol; Stanley Perlman
Journal:  Immunity       Date:  2020-07-14       Impact factor: 31.745

6.  Antigenic characterization of severe acute respiratory syndrome-coronavirus nucleocapsid protein expressed in insect cells: The effect of phosphorylation on immunoreactivity and specificity.

Authors:  Gu-Choul Shin; Yoon-Seok Chung; In-Soo Kim; Hae-Wol Cho; Chun Kang
Journal:  Virus Res       Date:  2007-05-11       Impact factor: 3.303

7.  A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease.

Authors:  Angkana T Huang; Bernardo Garcia-Carreras; Matt D T Hitchings; Bingyi Yang; Leah C Katzelnick; Susan M Rattigan; Brooke A Borgert; Carlos A Moreno; Benjamin D Solomon; Isabel Rodriguez-Barraquer; Justin Lessler; Henrik Salje; Donald Burke; Amy Wesolowski; Derek A T Cummings
Journal:  medRxiv       Date:  2020-04-17

8.  Enquête sérologique par immunofluorescence indirecte, sur les infections à coronavirus OC43.

Authors:  M Chambon; H Laveran; R L'Haridon; H Peigue-Lafeuille; M Trimolet; D Beytout
Journal:  Ann Inst Pasteur Virol       Date:  2009-09-23

9.  Viral infections and recurrences of febrile convulsions.

Authors:  H Rantala; M Uhari; H Tuokko
Journal:  J Pediatr       Date:  1990-02       Impact factor: 4.406

10.  Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.

Authors:  Yunfeng Zheng; Renfeng Li; Shunai Liu
Journal:  J Med Virol       Date:  2020-05-22       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.